Healthcare
NeuroPace, Inc.(NPCE)
Live Price
Offline$15.63
+3.10% today
Window Change
-5.50%
Window
May 29, 2026 โ Jun 18, 2026
- Market Cap
- $580.00M
- Revenue Growth
- +25.1%
- EPS Growth
- +29.0%
- Dividend Yield
- 0.0%
Historical coverage is still filling in
This 1Y daily history view is currently sparse. Use it as directional context while we continue backfilling more history.
Coverage: 15 bars ยท May 29, 2026 โ Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
NeuroPace, Inc. (NPCE) is a Healthcare stock with a market cap of $580.00M and listed on NASDAQ. The stock last traded around $15.63 and down 5.5% across the available one-year price window (May 29, 2026 โ Jun 18, 2026). Baseline metrics include revenue growth of +25.1%, EPS growth of +29.0%, a dividend yield of 0.0%. What stands out right now is revenue +25.1%, EPS +29.0%, free cash flow +37.9% with operating margin -16.3% and ROIC -18.2%. Valuation sits in the middle of the pack at price/sales 5.8. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines NPCE price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+25.1% vs +7.6% peer median
Operating Margin
Below sector median
-16.3% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 12, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +25.1% and EPS at +29.0%, with operating margin around -16.3%.
Benchmark Edge
NPCE vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
NPCE
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
NPCE Max Drawdown
-9.19%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for NPCE and SPY.
Company Overview
NeuroPace, Inc.
NASDAQ Global Market
NeuroPace, Inc. operates as a medical device company in the United States. It develops and sells RNS system, a brain-responsive neuromodulation system for treating medically refractory focal epilepsy by delivering personalized real-time treatment at the seizure source. The company's RNS system also records continuous brain activity data; and enables clinicians to monitor patients in person and remotely. It sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. The company was incorporated in 1997 and is headquartered in Mountain View, California.
- Leadership
- Joel D. Becker
- IPO Date
- Apr 22, 2021
- Employees
- 184
- Street Address
- 455 North Bernardo Avenue
- Mailing
- Mountain View, CA, 94043
- Region
- Mountain View, CA, US
- Reporting Currency
- USD
- Investor Line
- 650 237 2700
- Last Updated
- May 2, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 5.8
- Price/Book
- 29.4
Growth
- Revenue
- +25.1%
- EPS
- +29.0%
- Free Cash Flow
- +37.9%
Profitability
- Gross Margin
- 77.2%
- Operating Margin
- -16.3%
- Net Margin
- -21.5%
- ROE
- -105.7%
- ROIC
- -18.2%
Balance Sheet
- Debt/Equity
- 3.72
- Current Ratio
- 5.28
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.